Access Bio Inc Cash Flow-to-Debt Ratio
Access Bio Inc cash flow-to-debt ratio. Access Bio Inc (950130) has a Cash Flow-to-Debt Ratio of -0.14x as of June 2025, meaning its operating cash flow of ₩-9.16 Billion could theoretically repay 0% of its total liabilities (₩67.08 Billion) in one year. Check 950130 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Access Bio Inc (2012–2024)
Cash flow-to-debt ratio of Access Bio Inc from 2012 to 2024. Historical debt coverage capacity for Access Bio Inc across 13 annual periods. Check Access Bio Inc total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Access Bio Inc Cash Flow-to-Debt Ratio by Year (2012–2024)
Access Bio Inc cash flow-to-debt ratio by year from 2012 to 2024. Year-by-year debt coverage analysis for Access Bio Inc. For the full cash flow conversion analysis, see cash flow conversion of Access Bio Inc.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.22x | ₩13.54 Million | ₩61.70 Million | ▲ +28427.1% |
| 2023 | 0.00x | ₩-80.57 Million | ₩104.00 Billion | ▼ -100.1% |
| 2022 | 1.38x | ₩291.33 Million | ₩210.97 Million | ▲ +31.3% |
| 2021 | 1.05x | ₩137.90 Million | ₩131.10 Million | ▼ -99.8% |
| 2020 | 462.09x | ₩36.72 Billion | ₩79.47 Million | ▲ +4368.9% |
| 2019 | -10.82x | ₩-422.24 Million | ₩39.01 Million | ▲ +90.3% |
| 2018 | -111.49x | ₩-5.73 Billion | ₩51.40 Million | ▲ +5.8% |
| 2017 | -118.30x | ₩-5.45 Billion | ₩46.03 Million | ▼ -244657.5% |
| 2016 | 0.05x | ₩2.11 Million | ₩43.68 Million | ▼ -92.8% |
| 2015 | 0.68x | ₩2.87 Billion | ₩4.24 Billion | ▲ +365.5% |
| 2014 | -0.25x | ₩-2.63 Billion | ₩10.35 Billion | ▼ -244.2% |
| 2013 | 0.18x | ₩1.59 Billion | ₩8.99 Billion | ▼ -29.4% |
| 2012 | 0.25x | ₩1.85 Billion | ₩7.38 Billion | — |